Antimicrobial Peptides from Tasmanian Devils Kill MRSA and Drug-Resistant Superbugs with a 7x Safety Margin

Six cathelicidin peptides were characterized in Tasmanian devils. Saha-CATH5 and Saha-CATH6 showed broad-spectrum antibacterial activity, killing methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE). Saha-CATH3 had antifungal activity. Saha-CATH5 and 6 were toxic to human A549 cells at 500 μg/mL — over 7 times the pathogen-killing concentration. All six cathelicidins were widely expressed across immune tissues, digestive tract, respiratory tract, reproductive tract, milk, and pouch lining, indicating broad innate immune roles.

Cathelicidin genes were identified and characterized from Tasmanian devil genomic data. Synthetic peptides were produced and tested for antimicrobial activity against bacterial and fungal pathogens identified in the pouch microbiome, including antibiotic-resistant clinical isolates (MRSA, VRE). Cytotoxicity was assessed using human A549 lung epithelial cells. Tissue expression patterns were mapped to understand the peptides' roles in innate immunity and maternal-to-offspring immune transfer.

The antibiotic resistance crisis demands new antimicrobial approaches, and marsupial immune systems — evolved to protect the most vulnerable babies imaginable — represent an untapped source. Discovering peptides that kill both MRSA and VRE (two of the most dangerous hospital superbugs) with a good safety margin is significant. Marsupial peptides are structurally distinct from human cathelicidins, meaning bacteria haven't been exposed to them, potentially making resistance less likely to develop quickly.

Marsupials have evolved unique immune adaptations over millions of years of separate evolution from placental mammals. Mining their antimicrobial peptide repertoire has yielded promising candidates from opossums, wallabies, and now Tasmanian devils. These peptides have evolved independently from human defense peptides, giving them potentially novel mechanisms of action that resistant bacteria haven't encountered. The Tasmanian devil is particularly interesting because it faces additional immune challenges from devil facial tumor disease.

In vitro antimicrobial and cytotoxicity testing only — no in vivo efficacy studies were performed. Three of six cathelicidins showed no activity against tested organisms (though they were widely expressed, suggesting unidentified roles). The A549 cytotoxicity assay represents only one cell type. Stability, pharmacokinetics, and immunogenicity of Tasmanian devil peptides in mammalian systems were not assessed. The tested pathogens were limited to selected strains, and activity against Gram-negative superbugs was not specifically reported.